Danpanichkul, Pojsakorn
Suparan, Kanokphong
Sukphutanan, Banthoon
Kaeosri, Chuthathip
Tothanarungroj, Primrose
Sirimangklanurak, Supapitch
Kalligeros, Markos
Polpichai, Natchaya
Pang, Yanfang
Wijarnpreecha, Karn
Sripongpun, Pimsiri
Chamroonkul, Naichaya
Nguyen, Mindie H.
Liangpunsakul, Suthat
Piratvisuth, Teerha
Kaewdech, Apichat
Funding for this research was provided by:
Faculty of Medicine, Prince of Songkla University
Article History
Received: 24 May 2024
Accepted: 19 August 2024
First Online: 22 August 2024
Competing interests
: Teerha Piratvisuth received research grants from Gilead Sciences, Roche Diagnostics, Janssen, Fibrogen, and VIR and honoraria from Bristol-Myers Squibb, Gilead Sciences, Bayer, Abbott, Esai, Mylan, Ferring, and MSD. Mindie H. Nguyen received research support from Pfizer, Enanta, Astra Zeneca, GSK, Delfi, Innogen, Exact Science, CurveBio, Gilead, Vir Biotech, Helio Health, National Cancer Institute, Glycotest, National Health Institute and is a consultant and/or advisory board of GSK, Gilead, and Exelixis. Dr. Liangpunsakul discloses consulting roles with Durect Corporation, Surrozen, and Korro Bio. However, these roles do not present any conflict of interest concerning the content of this work. Apichat Kaewdech received research grants or support from Roche, Roche Diagnostics, and Abbott Laboratories, and honoraria from Roche, Roche Diagnostics, Abbott Laboratories, and Esai. The other authors have no relevant conflict of interest to declare.